Neumora Therapeutics Discounted Cash Flow

The latest DCF fair value for NMRA is $1.1. Investors often review this figure alongside Neumora Therapeutics's historical trend and sector peers before judging valuation or financial health.

A DCF fair value of $1.1 for Neumora Therapeutics suggests the stock may be undervalued by roughly 157.3% at today's price. That does not mean the market is 'wrong'; it means the model's cash-flow assumptions imply a different intrinsic value. Stress-test the estimate by comparing it with historical valuation ranges and peer multiples.

After noting NMRA's DCF fair value ($1.1), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.